Key Points
- EVP Aby Mathew sold 405 shares on January 6 at an average price of $25.59 for $10,363.95, and still holds 349,350 shares (≈$8.94M), a 0.12% reduction in ownership disclosed in an SEC Form 4 filing.
- BioLife (NASDAQ:BLFS) is trading near $24.95 with a market cap of $1.20 billion, a negative P/E of -356.38 and a 52‑week range of $19.10–$29.62, reflecting recent volatility.
- Analyst coverage is mixed — three Buys, one Hold and one Sell — producing a MarketBeat consensus rating of "Hold" and an average price target of $32.00, with recent notes including UBS reiterating Buy and Weiss Ratings at Sell.
BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby Mathew sold 405 shares of the firm's stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total value of $10,363.95. Following the completion of the transaction, the executive vice president owned 349,350 shares of the company's stock, valued at approximately $8,939,866.50. The trade was a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
BioLife Solutions Stock Performance
Shares of BLFS opened at $24.95 on Friday. The business's 50-day moving average is $25.47 and its two-hundred day moving average is $24.81. The company has a market capitalization of $1.20 billion, a P/E ratio of -356.38 and a beta of 1.93. BioLife Solutions, Inc. has a fifty-two week low of $19.10 and a fifty-two week high of $29.62.
Analyst Upgrades and Downgrades
BLFS has been the topic of several research reports. Northland Securities set a $34.00 target price on BioLife Solutions in a research report on Monday. Weiss Ratings restated a "sell (d-)" rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Wall Street Zen lowered shares of BioLife Solutions from a "buy" rating to a "hold" rating in a report on Sunday, November 30th. Zacks Research cut shares of BioLife Solutions from a "strong-buy" rating to a "hold" rating in a research report on Monday, December 8th. Finally, UBS Group restated a "buy" rating on shares of BioLife Solutions in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, BioLife Solutions has a consensus rating of "Hold" and an average price target of $32.00.
Read Our Latest Stock Report on BioLife Solutions
Hedge Funds Weigh In On BioLife Solutions
Several hedge funds have recently added to or reduced their stakes in the stock. State of Wyoming boosted its stake in BioLife Solutions by 353.1% in the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 1,490 shares in the last quarter. Hantz Financial Services Inc. grew its holdings in shares of BioLife Solutions by 54.1% during the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider's stock worth $48,000 after buying an additional 659 shares during the last quarter. Quarry LP increased its holdings in shares of BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider's stock valued at $54,000 after purchasing an additional 713 shares during the period. Ameritas Investment Partners Inc. increased its stake in BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock valued at $83,000 after buying an additional 441 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in shares of BioLife Solutions by 82.0% during the third quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider's stock worth $113,000 after acquiring an additional 1,994 shares during the period. 93.24% of the stock is currently owned by hedge funds and other institutional investors.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.
The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
